{"denoms":[{"counts":[{"groupId":"BG000","value":"431"},{"groupId":"BG001","value":"430"},{"groupId":"BG002","value":"861"}],"units":"Participants"}],"groups":[{"description":"ABI-007 125 mg/m\\^2 administered in combination with gemcitabine 1000 mg/m\\^2 weekly for 3 weeks followed by one week of rest.\n\nAlbumin-bound paclitaxel (ABI-007)/Gemcitabine : ABI-007 125 mg/m\\^2 administered in combination with Gemcitabine 1000 mg/m\\^2 weekly for 3 weeks, Days 1, 8, and 15 followed by one week of rest","id":"BG000","title":"Albumin-bound Paclitaxel (ABI-007)/Gemcitabine"},{"description":"Gemcitabine, 1000 mg/m\\^2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).\n\nGemcitabine : Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).","id":"BG001","title":"Gemcitabine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.70","value":"61.4"},{"groupId":"BG001","spread":"9.27","value":"63.0"},{"groupId":"BG002","spread":"10.04","value":"62.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"173"},{"groupId":"BG002","value":"359"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"502"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"32"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"378"},{"groupId":"BG001","value":"375"},{"groupId":"BG002","value":"753"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"51"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"138"}]}],"title":"100% = normal, no complaints, no signs of disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"378"}]}],"title":"90% = normal activity, few symptoms of disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"277"}]}],"title":"80% = normal activity, some symptoms of disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"63"}]}],"title":"70% = caring for self, unable to work"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"60% = needs help, can manage most tasks"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"50% = needs help often and medical care"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"40% = disabled; requires special care & assistance"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"30% = severely disabled; death is imminent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"20% = hospitalized; requires supportive treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"10% = Moribund, fatal processes progressing fast"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"0% = Dead"}],"description":"The Karnofsky Performance Status Scale (KPS) was designed to measure the level of participant activity and medical care requirements. A general measure of participant independence and has been widely used as a general assessment of participants with cancer. The Karnofsky score runs from 100 to 0, where 100 is \"perfect\" health and 0 is death. The primary purpose of its development was to allow physicians to evaluate a participant's ability to survive chemotherapy for cancer. Two participants from the Albumin bound paclitaxel arm and one from the Gemcitabine arm did not have KPS performed.","paramType":"NUMBER","title":"Karnofsky Performance Status (KPS)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"191"},{"groupId":"BG001","value":"180"},{"groupId":"BG002","value":"371"}]}],"title":"Head"},{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"268"}]}],"title":"Body"},{"categories":[{"measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"215"}]}],"title":"Tail"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}],"title":"Unknown = not specified"}],"description":"Main location or area of the pancreas where the disease is detected at diagnosis. Unknown location refers to disease area not being specified.","paramType":"NUMBER","title":"Pancreatic Primary Tumor Location","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"57"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}]}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"80"}]}],"title":"4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}]}],"title":"5"},{"categories":[{"measurements":[{"groupId":"BG000","value":"276"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"538"}]}],"title":">5"}],"description":"Target lesions are those measurable at baseline and are generally the largest lesions, most reliably measured and most representative of the participants sites of disease. Non target lesions are all of the sites of disease present at baseline not classified as target lesions. They include bone and cystic lesions and pleural/pericardial effusion/ascites. The Independent Radiology Reviewers (IRR) only evaluated scans for those with baseline and follow-up scans.","paramType":"NUMBER","title":"Number of Baseline Lesions (Target + Non-Target)","unitOfMeasure":"participants"}],"populationDescription":"For the Karnofsky Performance Status (KPS) baseline characteristic, some of the participants did not have a baseline KPS recorded by the clinical site."}